CL2018002335A1 - Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1 - Google Patents
Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1Info
- Publication number
- CL2018002335A1 CL2018002335A1 CL2018002335A CL2018002335A CL2018002335A1 CL 2018002335 A1 CL2018002335 A1 CL 2018002335A1 CL 2018002335 A CL2018002335 A CL 2018002335A CL 2018002335 A CL2018002335 A CL 2018002335A CL 2018002335 A1 CL2018002335 A1 CL 2018002335A1
- Authority
- CL
- Chile
- Prior art keywords
- acetylcholine receptor
- positive allosteric
- allosteric modulators
- muscarinic acetylcholine
- compositions
- Prior art date
Links
- 102000018154 Muscarinic acetylcholine receptor M1 Human genes 0.000 title 1
- 108050007299 Muscarinic acetylcholine receptor M1 Proteins 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003551 muscarinic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296012P | 2016-02-16 | 2016-02-16 | |
| US201662402438P | 2016-09-30 | 2016-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018002335A1 true CL2018002335A1 (es) | 2019-02-01 |
Family
ID=59626207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002335A CL2018002335A1 (es) | 2016-02-16 | 2018-08-14 | Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11111251B2 (enExample) |
| EP (1) | EP3416639B1 (enExample) |
| JP (1) | JP2019504901A (enExample) |
| KR (1) | KR20180110132A (enExample) |
| CN (1) | CN109069491A (enExample) |
| AU (1) | AU2017221404A1 (enExample) |
| BR (1) | BR112018016689A2 (enExample) |
| CA (1) | CA3014791A1 (enExample) |
| CL (1) | CL2018002335A1 (enExample) |
| EA (1) | EA201891854A1 (enExample) |
| IL (1) | IL261058A (enExample) |
| MA (1) | MA44253A (enExample) |
| MX (1) | MX385975B (enExample) |
| PH (1) | PH12018501731A1 (enExample) |
| WO (1) | WO2017143041A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3507289T3 (pl) * | 2016-09-02 | 2021-01-25 | Suven Life Sciences Limited | Dodatnie allosteryczne modulatory receptora muskarynowego m1 |
| EA035599B1 (ru) * | 2017-04-13 | 2020-07-14 | Сувен Лайф Сайенсиз Лимитед | Позитивные аллостерические модуляторы мускариновых m1-рецепторов |
| US11236099B2 (en) * | 2017-06-20 | 2022-02-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR102658949B1 (ko) * | 2017-06-20 | 2024-04-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 |
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2019082140A1 (en) | 2017-10-27 | 2019-05-02 | Suven Life Sciences Limited | POLYCYCLIC AMIDES AS POSITIVE ALLOSTERIC MODULATORS OF M1 MUSCARINIC RECEPTOR |
| ES2982890T3 (es) | 2017-10-31 | 2024-10-18 | Univ Vanderbilt | Antagonistas del receptor muscarínico de acetilcolina M4 |
| CA3090130A1 (en) | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019241467A1 (en) * | 2018-06-13 | 2019-12-19 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US12162864B2 (en) | 2018-09-28 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Condensed-cyclic compound |
| JP7443238B2 (ja) | 2018-09-28 | 2024-03-05 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3643711A1 (en) * | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| WO2020086864A1 (en) | 2018-10-24 | 2020-04-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US12319701B2 (en) | 2019-10-04 | 2025-06-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4608079A (en) | 1983-08-02 | 1986-08-26 | American Cyanamid Company | Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| JP2002539130A (ja) | 1999-03-09 | 2002-11-19 | ファルマシア・アンド・アップジョン・カンパニー | 抗ウイルス剤としての４−オキソ−４，７−ジヒドロ−チエノ［２，３−ｂ］ピリジン−５−カルボキサミド |
| TWI310035B (en) * | 2000-04-28 | 2009-05-21 | Acadia Pharm Inc | Muscarinic agonists |
| CZ2004408A3 (cs) | 2001-10-02 | 2005-03-16 | Pharmacia & Upjohn Company | Azabicyklicky substituované kondenzované heteroarylsloučeniny |
| AU2010340142B2 (en) * | 2009-12-17 | 2014-05-08 | Merck Sharp & Dohme Corp. | Quinoline amide M1 receptor positive allosteric modulators |
| WO2011159554A1 (en) | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| WO2012158474A1 (en) * | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
| WO2015027204A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| GB201317363D0 (en) * | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| RU2016132858A (ru) | 2014-01-22 | 2018-03-02 | Ф. Хоффманн-Ля Рош Аг | Производные фторнафтила |
| EP3156397B1 (en) | 2014-06-13 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| PL3507289T3 (pl) | 2016-09-02 | 2021-01-25 | Suven Life Sciences Limited | Dodatnie allosteryczne modulatory receptora muskarynowego m1 |
-
2017
- 2017-02-16 BR BR112018016689A patent/BR112018016689A2/pt not_active IP Right Cessation
- 2017-02-16 CA CA3014791A patent/CA3014791A1/en active Pending
- 2017-02-16 WO PCT/US2017/018140 patent/WO2017143041A1/en not_active Ceased
- 2017-02-16 EP EP17753822.0A patent/EP3416639B1/en active Active
- 2017-02-16 CN CN201780023438.3A patent/CN109069491A/zh active Pending
- 2017-02-16 MA MA044253A patent/MA44253A/fr unknown
- 2017-02-16 KR KR1020187026643A patent/KR20180110132A/ko not_active Withdrawn
- 2017-02-16 US US15/998,899 patent/US11111251B2/en active Active
- 2017-02-16 EA EA201891854A patent/EA201891854A1/ru unknown
- 2017-02-16 JP JP2018561928A patent/JP2019504901A/ja active Pending
- 2017-02-16 AU AU2017221404A patent/AU2017221404A1/en not_active Abandoned
- 2017-02-16 MX MX2018009952A patent/MX385975B/es unknown
-
2018
- 2018-08-08 IL IL261058A patent/IL261058A/en unknown
- 2018-08-14 CL CL2018002335A patent/CL2018002335A1/es unknown
- 2018-08-15 PH PH12018501731A patent/PH12018501731A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11111251B2 (en) | 2021-09-07 |
| MA44253A (fr) | 2018-12-26 |
| BR112018016689A2 (pt) | 2019-02-12 |
| IL261058A (en) | 2018-10-31 |
| CA3014791A1 (en) | 2017-08-24 |
| US20210230180A1 (en) | 2021-07-29 |
| MX2018009952A (es) | 2018-11-29 |
| EP3416639B1 (en) | 2022-06-08 |
| JP2019504901A (ja) | 2019-02-21 |
| EA201891854A1 (ru) | 2019-01-31 |
| EP3416639A4 (en) | 2019-07-03 |
| CN109069491A (zh) | 2018-12-21 |
| EP3416639A1 (en) | 2018-12-26 |
| WO2017143041A1 (en) | 2017-08-24 |
| MX385975B (es) | 2025-03-18 |
| AU2017221404A1 (en) | 2018-08-23 |
| KR20180110132A (ko) | 2018-10-08 |
| PH12018501731A1 (en) | 2019-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385975B (es) | Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
| CL2016001983A1 (es) | Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4 | |
| MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
| ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| CL2016002751A1 (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CL2018000883A1 (es) | Moduladores del receptor x farnesoide | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| MX2016014773A (es) | Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico. | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| BR112016025470A2 (pt) | ?hdl terapêutico? | |
| CL2016002497A1 (es) | “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct | |
| ECSP17081322A (es) | Moduladores alostéricos positivos del receptor muscarínico m2 | |
| CL2019001330A1 (es) | Inhibidores de la tirosina quinasa de bruton. | |
| ECSP21016032A (es) | Inhibidores de la interacción proteína-proteína keap1-nrf2 | |
| AR109752A1 (es) | Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis | |
| CL2016000726A1 (es) | Derivados de 4-azaindol | |
| CR20170076A (es) | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| MX394089B (es) | Nuevos derivados de xantina sustituidos. | |
| CO2018011420A2 (es) | Formulaciones líquidas de fosfaplatino |